Cargando…
Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation
SIMPLE SUMMARY: Pancreatic ductal adenocarcinoma is a devastating disease. Using modern technique of radiotherapy, such as proton therapy, may simultaneously enhance dose to the tumor and decrease dose to surrounding organ, thus limiting toxicity. Moreover, associating drugs to radiotherapy also inc...
Autores principales: | Waissi, Waisse, Nicol, Anaïs, Jung, Matthieu, Rousseau, Marc, Jarnet, Delphine, Noel, Georges, Burckel, Hélène |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866541/ https://www.ncbi.nlm.nih.gov/pubmed/33573176 http://dx.doi.org/10.3390/cancers13030527 |
Ejemplares similares
-
Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines
por: Waissi, Waisse, et al.
Publicado: (2021) -
Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
por: Lesueur, Paul, et al.
Publicado: (2017) -
Impact of proton therapy on antitumor immune response
por: Mirjolet, Céline, et al.
Publicado: (2021) -
Prognostic Factors in Extremity Soft Tissue Sarcomas Treated with Radiotherapy: Systematic Review of the Literature
por: Lebas, Arthur, et al.
Publicado: (2023) -
Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview
por: Antoni, Delphine, et al.
Publicado: (2021)